EMA Committee Backs Remicade Biosimilar Zessly EMA Committee Backs Remicade Biosimilar Zessly

The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn ' s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news